血管紧张素转换酶2在SARS-CoV-2感染中的作用机制研究进展

摘要
图/表
参考文献(0)
相关文章 (1)

全文: PDF (790 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要引发新型冠状病毒肺炎的病原体SARS-CoV-2为单股正链RNA病毒，传染性强，已在世界范围内多个国家传播，成为全球关注的热点。研究表明血管紧张素转换酶2（angiotensin converting enzyme 2，ACE2）可能是SARS-CoV-2 感染宿主的受体，因而了解SARS-CoV-2作用于ACE2的不同机制对于开发治疗性药物和疫苗研发具有重要参考价值。本文综述了ACE2在机体不同组织表达情况与组织损伤的关系，ACE2参与免疫炎症的调节过程及年龄、性别、不同基础疾病等因素对ACE2表达和组织损伤的机制进展。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王荟1
	2
	吕巧怡1
	赵杨静1
	吴皓杰1
	邵启祥1
	2

关键词 ：重症急性呼吸道综合征冠状病毒2, 血管紧张素转化酶2, S蛋白

收稿日期: 2020-05-22

基金资助:国家自然科学基金资助项目(81701545，81671541)

通讯作者: 邵启祥（通讯作者），教授，博士生导师，E-mail：shao_qx@ ujs.edu.cn

作者简介: 王荟(1988—)，女，副教授，硕士生导师

引用本文:

王荟1,2，吕巧怡1，赵杨静1，吴皓杰1，邵启祥1,2. 血管紧张素转换酶2在SARS-CoV-2感染中的作用机制研究进展[J]. 江苏大学学报:医学版, 2021, 31(01): 88-92.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2021/V31/I01/88

［1］Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern\[J\]. Lancet, 2020, 395(10223): 470-473.

［2］Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin\[J\]. Nature, 2020, 579(7798): 270-273.

［3］Xiao F, Tang M, Zheng X, et al. Evidence for castrointestinal infection of SARSCoV2\[J\]. Gastroenterology, 2020, 158(6): 1831-1833.

［4］Jiang S, Xia S, Ying T, et al. A novel coronavirus (2019nCoV) causing pneumoniaassociated respiratory syndrome\[J\]. Cell Mol Immunol, 2020, 17(5): 554.

［5］Wu Z, Mcgoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention\[J\]. JAMA, 2020. doi: 10.1001/jama.2020.2648.

［6］Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARSCoV2 by fulllength human ACE2\[J\]. Science, 2020, 367(6485): 1444-1448.

［7］Lan J, Ge J, Yu J, et al. Structure of the SARSCoV2 spike receptorbinding domain bound to the ACE2 receptor\[J\]. Nature, 2020, 581(7807): 215-220.

［8］Wrapp D, Wang N, Corbett KS, et al. CryoEM structure of the 2019nCoV spike in the prefusion conformation\[J\]. Science, 2020, 367(6483): 1260-1263.

［9］Walls A, Park Y, Tortorici M, et al. Structure, function, and antigenicity of the SARSCoV2 spike glycoprotein\[J\]. Cell, 2020, 181(2): 281-292.

［10］Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARSCoV2\[J\]. Nature, 2020, 581(7807): 221-224.

［11］Braun E, Sauter D. Furinmediated protein processing in infectious diseases and cancer\[J\]. Clin Transl Immunology, 2019, 8(8): e1073.

［12］Zou X, Chen K, Zou J, et al. Singlecell RNAseq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019nCoV infection\[J\]. Front Med, 2020, 14(2): 185-192.

［13］Bao L, Deng W, Huang B, et al. The pathogenicity of SARSCoV2 in hACE2 transgenic mice\[J\]. Nature, 2020, 583(7818): 830-833.

［14］Liang W, Feng Z, Rao S, et al. Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus\[J\]. Gut, 2020, 69(6): 1141-1143.

［15］Song Y, Liu P, Shi X, et al. SARSCoV2 induced diarrhoea as onset symptom in patient with COVID19\[J\]. Gut, 2020, 69(6): 1143-1144.

［16］Chai P, Yu J, Ge S, et al. Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID19) receptor ACE2 in malignancies: a pancancer analysis\[J\]. J Hematol Oncol, 2020, 13(1): 43.

［17］Cao Y, Li L, Feng Z, et al. Comparative genetic analysis of the novel coronavirus (2019nCoV/SARSCoV2) receptor ACE2 in different populations\[J\]. Cell Discov, 2020, 6(1): 11.

［18］Fu Y, Cheng Y, Wu Y. Understanding SARSCoV2mediated inflammatory responses: from mechanisms to potential therapeutic tools\[J\]. Virol Sin, 2020, 35(3): 266-271.

［19］Monteil V, Kwon H, Prado P, et al. Inhibition of SARSCoV2 infections in engineered human tissues using clinicalgrade soluble human ACE2\[J\]. Cell, 2020, 181(4): 905-913.

［20］Chen L, Zhong L. Lung adenocarcinoma patients own higher risk of SARSCoV2 infection\[J\]. Preprints, 2020, 202002.0386.v1

［21］Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID19\[J\]. Lancet, 2020, 395(10234): 1417-1418.

［22］Ziegler C, Allon S, Nyquist S, et al. SARSCoV2 receptor ACE2 is an interferonstimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues\[J\]. Cell, 2020, 181(5): 1016-1035.

［23］Sungnak W, Huang N, Bécavin C, et al. SARSCoV2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes\[J\]. Nat Med, 2020, 26(5): 681-687.

［24］Li M, Li L, Zhang Y, et al. An investigation of the expression of 2019 novel coronavirus cell receptor gene ACE2 in a wide variety of human tissues\[J\]. Research Square, 2020. doi: 10.21203/rs.2.24751/v2.

［25］Hamming I, Timens W, Bulthuis M, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis\[J\]. J Pathol, 2004, 203(2): 631-637.

［26］Smith J, Sausville E, Girish V, et al. Cigarette smoke exposure and inflammatory signaling increase the expression of the SARSCoV2 receptor ACE2 in the respiratory tract\[J\]. Dev Cell, 2020, 53(5): 514-529.

［27］Song H, Seddighzadeh B, Cooperberg M, et al. Expression of ACE2, the SARSCoV2 receptor, and TMPRSS2 in prostate epithelial cells\[J\]. Eur Urol, 2020, 78(2): 296-298.

［28］Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study\[J\]. Lancet, 2020, 395(10223): 507-513.

［29］Hoffmann M, KleineWeber H, Schroeder S, et al. SARSCoV2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor\[J\]. Cell, 2020, 181(2): 271-280.

［30］Li J, Zhang Y, Wang F, et al. Sex differences in clinical findings among patients with coronavirus disease 2019 (COVID19) and severe condition\[J\]. medRxiv, 2020. doi: 10.1101/2020.02.27.20027524.

［31］Srensen M, Srensen B, GonzalezDosal R, et al. Severe acute respiratory syndrome (SARS): development of diagnostics and antivirals\[J\]. Ann N Y Acad Sci, 2006, 1067: 500-505.

［32］Park J, Jung S, Kim A, et al. MERS transmission and risk factors: a systematic review\[J\]. BMC Public Health, 2018, 18(1): 574.

［33］Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China\[J\]. NEJM, 2020, 382(18): 1708-1720.

［34］Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread\[J\]. J Virol, 2005, 2(1): 69.

［35］Henry C, Zaizafoun M, Stock E, et al. Impact of angiotensinconverting enzyme inhibitors and statins on viral pneumonia\[J\]. Proc (Bayl Univ Med Cent), 2018, 31(4): 419-423.

［36］Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirusspecific human monoclonal antibody\[J\]. Emerg Microbes Infect, 2020, 9(1): 382-385.

［37］Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARSCoV2 infection\[J\]. Nature, 2020, 584: 115-119.

［38］Chen X, Li R, Pan Z, et al. Human monoclonal antibodies block the binding of SARSCoV2 spike protein to angiotensin converting enzyme 2 receptor\[J\]. Cell Mol Immunol, 2020, 17(6): 647-649.

［39］Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID19\[J\]. Nat Rev Immunol, 2020, 20(6): 339-341.

［40］Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID19 patients\[J\]. Proc Natl Acad Sci U S A, 2020, 117(17):9490-9496.

［41］Amanat F, Krammer F. SARSCoV2 vaccines: status report\[J\]. Immunity, 2020, 52(4): 583-589.